2023 Fiscal Year Final Research Report
Assessment of cognitive impairment using high-performance eye tracking technology in prostate cancer
| Project/Area Number |
20K09547
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56030:Urology-related
|
|---|
| Research Institution | Dokkyo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
井手 久満 順天堂大学, 医学部, 教授 (00301383)
武田 朱公 大阪大学, 大学院医学系研究科, 寄附講座准教授 (50784708)
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Keywords | 前立腺癌 |
|---|
| Outline of Final Research Achievements |
Developments in hormone therapy, including new anti-androgen drugs, and chemotherapy have significantly contributed to the survival rate of prostate cancer patients. However, lower testosterone levels are involved in the progression and prevention of various diseases such as angina, arteriosclerosis, obesity, metabolic syndrome, and dementia. In particular, cognitive decline is a socially significant issue. The extent of gaze movement disorders (such as decreased speed of eye movements, biased fixation points, and impairments in memory tasks) during and after androgen deprivation therapy was quantified and correlated with cognitive function in subjects. As a result, cognitive decline measured by gaze tracking could not be detected at 3, 6, and 12 months during androgen deprivation therapy.
|
| Free Research Field |
泌尿器科学
|
| Academic Significance and Societal Importance of the Research Achievements |
前立腺癌患者における認知症のリスクファクターとしては、高年齢、内分泌療法の期間、アルコール摂取、喫煙、運動不足などがあるが、アンドロゲン除去療法によるこれらの背景因子の検討はなされていない。また、治療介入としては、これらのリスクファクターを減らすようなライフスタイルの改善と認知機能改善のための薬物療法が考えられるが、これまでの報告は極めて少ない。視線追跡装置による認知症の客観的・定量的な評価が、認知症初期段階から可能になれば、客観的なデータに基づいた投薬やリハビリテーションに繋がり、泌尿器科の医療の現場で革新的な変化を起こすことが期待される。
|
